Phase II pilot study of single-agent etirinotecan pegol (NKTR-102) in bevacizumab-resistant high grade glioma

Patients with recurrence of high-grade glioma (HGG) after bevacizumab (BEV) have an extremely poor prognosis. Etirinotecan pegol (EP) is the first long-acting topoisomerase-I inhibitor designed to concentrate in and provide continuous tumor exposure throughout the entire chemotherapy cycle. Here we...

Descripción completa

Detalles Bibliográficos
Autores principales: Nagpal, Seema, Recht, Cathy Kahn, Bertrand, Sophie, Thomas, Reena Parada, Ajlan, Abdulrazag, Pena, Justine, Gershon, Megan, Coffey, Gwen, Kunz, Pamela L., Li, Gordon, Recht, Lawrence D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2015
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4452613/
https://www.ncbi.nlm.nih.gov/pubmed/25935109
http://dx.doi.org/10.1007/s11060-015-1795-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4452613/
https://www.ncbi.nlm.nih.gov/pubmed/25935109
http://dx.doi.org/10.1007/s11060-015-1795-0

Ejemplares similares